Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.
All females of childbearing potential must have a blood test or urine study within 2 weeks prior to Step 1 Randomization to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1 has achieved menarche at some point, 2 has not undergone a hysterectomy or bilateral oophorectomy; or 2 has not been naturally postmenopausal amenorrhea following cancer therapy does not rule out childbearing potential for at least 24 consecutive months i.
OncologyResearchSupport providence. Stevenson foundationhealth. Boucher providence. Research rushcopley. Smith3 nm. Norris LMH. Werle mercy.
Gonzales rwjbh. Dodd providence. To compare patterns of failure local and regional relapse versus distant; in-field versus out-of-field of radiation , disease control, and overall survival between experimental and control arm. To correlate vaginal dilator use during radiation delivery with sexual function. To measure changes in serum total testosterone from baseline to up to 12 months after radiation.
To validate the utility of imaging features of inguinal and pelvic lymph nodes obtained prior to treatment as a prognostic indicator that can identify patients with early-stage anal squamous cell carcinoma for whom treatment with de-intensified chemoradiation is appropriate. To determine the incidence of and predictors for cardiovascular toxicity in patients receiving fluorouracil 5-FU or capecitabine.
